Here's a story that explains a lot about where psychedelic medicine is heading. A mother, a physician, watches her son collapse under the weight of OCD and depression. She reads everything. One night she stumbles on a small 2006 study suggesting psilocybin — the compound in magic mushrooms — might quiet the obsessive loops that conventional medicine couldn't touch. She finds an underground guide. Her son drinks the tea. Six hours later, something shifts. He goes back to school. He gets his life back.

That family went on to launch a company now worth roughly $400 million, listed on the Nasdaq, running one of the largest psilocybin trials in history. For anyone researching ayahuasca, psilocybin, or other plant medicines as a way out of addiction, depression, or trauma, the rise of Compass Pathways is worth understanding. It's reshaping the whole landscape — including the retreat world you're probably reading about right now.

From a Dorm Room Crisis to a Clinical-Grade Drug

The origin story matters because it explains the tension. Ekaterina Malievskaia and George Goldsmith weren't pharmaceutical executives. They were parents. After watching their son emerge from a single supervised psilocybin session looking like himself again — sleeping, exercising, returning to class — they did what desperate, well-resourced parents do. They threw money at the problem. Hundreds of thousands of dollars into psychedelic nonprofits. A small project on the Isle of Man offering psilocybin to hospice patients. A nonprofit called C.O.M.P.A.S.S. to bring these treatments to people who'd run out of options.

Then, in 2016, they pivoted. The nonprofit shut down. A for-profit corporation launched in London. The reasoning, as they tell it: you cannot move a drug through regulatory approval on donations alone. The price tag for late-stage trials runs into the hundreds of millions. To reach the people who needed psilocybin most — the ones whose insurance might one day cover it — they needed venture capital, not philanthropy.

That pivot didn't sit well with everyone. Several researchers and longtime advocates who'd helped them in their nonprofit days felt blindsided. Some still do. The argument that follows them around — that you can't ethically commercialize a sacrament — is one the company has spent years answering.

Why Billionaires Suddenly Cared About Mushrooms

By 2017, three names had quietly placed bets on Compass: Christian Angermayer (a German entrepreneur who'd had his own psilocybin experience and become an evangelist), Michael Novogratz (the crypto investor), and Peter Thiel (the PayPal cofounder). Each put in roughly a million pounds. Novogratz's framing was almost charmingly blunt — he'd taken a flyer on cryptocurrencies and made a fortune, so why not a flyer on something equally fringe?

The money kept coming. A £25 million round in 2018. An $80 million Series B in 2019, then a record for the sector. A Nasdaq IPO in 2020 at a billion-dollar valuation. The company is now running a Phase 3 trial with nearly a thousand participants, testing a synthetic form of psilocybin (they call it COMP360) against treatment-resistant depression — the cases where SSRIs, talk therapy, and everything else have already failed.

Analysts have floated peak sales numbers somewhere between $1.1 billion and $8 billion if the drug clears approval and gets expanded for other mental-health conditions. The first approvals could land as early as 2026. That's not a footnote. That's the medical mainstream walking into a room it's been locked out of since the 1960s.

What This Has to Do With Plant Medicine Retreats

You might be wondering why a story about a publicly traded pharmaceutical company matters if you're researching, say, an ayahuasca retreat in Peru or a psilocybin ceremony in Jamaica. Fair question. Here's the honest answer: the two worlds are bleeding into each other, and the choices you make as a retreat-seeker are going to be shaped by what happens in those clinical trials over the next two years.

A few things are likely to shift:

• Legitimacy. Once psilocybin has an FDA label for treatment-resistant depression, the conversation around plant medicine stops being fringe at dinner parties. Your skeptical sibling becomes easier to talk to. Your therapist may even bring it up first.
• Access and price. A clinic-based psilocybin session under medical supervision will almost certainly cost more than most retreats — early estimates from Oregon's regulated program already put sessions in the thousands of dollars, often without insurance coverage at launch. A traditional retreat in the Amazon or a psilocybin gathering in the Netherlands may remain a more affordable route for many people.
• What you actually get. A clinical session is sterile, measured, and explicitly medical. A ceremonial setting — whether it's ayahuasca with a curandero, San Pedro at altitude, or a psilocybin retreat run by experienced facilitators — offers something different: ritual, community, integration with people who've been through it. Neither is universally better. They're answering different questions.
• The addiction angle. Most of the clinical work focuses narrowly on depression and PTSD. If you're considering plant medicine for addiction — alcohol, opioids, stimulants, compulsive behaviors — the retreat world (and ibogaine clinics specifically) is still where the deepest practical experience lives. Compass isn't running an addiction trial. Yet.

Is Ayahuasca or Psilocybin Right for What You're Carrying?

This is the question I get asked most often by people deciding whether to book. The answer isn't binary, and anyone who tells you it is — on either side — is selling something.

Plant medicine, when it works, doesn't work because the molecule is magic. It works because the molecule cracks something open, and what you do with the opening matters more than the opening itself. The single session that turned Allan Malievsky's life around wasn't just six hours of psilocybin. It was a darkened room, a trusted guide, music chosen with care, and — crucially — a family ready to support whatever came next. The medicine was the catalyst. The container was the cure.

This is why master plants — ayahuasca, peyote, San Pedro, iboga, the whole lineage — have always been used inside ritual frameworks. The Shipibo curanderos in the Peruvian Amazon haven't been running clinical trials, but they have been refining a practice over generations. There's wisdom there that no Phase 3 protocol can replicate. There's also, let's be honest, plenty of charlatanism out there too. Both things are true.

If you're weighing a retreat, a few honest filters worth running:

1. What are you actually trying to address? Vague "growth" rarely justifies the risk and expense. A specific pattern — a depression that hasn't budged in years, a drinking habit you can't put down, a grief you can't process — gives the experience something to work on.
2. Are you medically eligible? Certain SSRIs, MAOIs, and heart conditions are genuine contraindications for ayahuasca. A reputable retreat will screen you carefully. If they don't ask about your medications, walk away.
3. Who's holding the space? Years of experience, references from past participants, transparent emergency protocols. Not vibes. Not Instagram.
4. What's the integration plan? A retreat without integration support is a vacation with a hangover. The week after often matters more than the ceremony itself.

The Controversy Worth Knowing About

Compass has earned its share of critics, and the criticism is worth understanding before you form an opinion. Some of it centers on patent applications that activists argued were overreaching — attempts, they said, to lock down techniques that the broader community considered shared heritage. Some of it is more philosophical: the discomfort with anyone profiting from substances that Indigenous communities have stewarded for centuries without commercial interest.

You can think both things at the same time. You can be glad that millions of people with treatment-resistant depression may soon have a real option, and uneasy about the consolidation of plant medicine into corporate IP portfolios. The retreat world tends to live closer to the older, communal model. The clinical world is heading somewhere very different. Where you land on that spectrum will shape what kind of healing path makes sense for you.

What to Do With All This If You're Still Deciding

Read more than the marketing. Talk to people who've actually sat in ceremony — not the ones writing breathless trip reports, but the ones who can tell you what their life looked like six months later. Pay attention to whether they sound like they're still chasing the experience or whether they've integrated it and moved on. The second group is who you want to learn from.

And give yourself permission to wait. The clinical trials will keep running. The retreats will still be there next year. If you're in acute crisis, that's a different conversation — find a clinician, find support, don't make a major decision while drowning. But if you're in the careful research phase, careful is good. This is real medicine, and real medicine deserves real preparation.

If something here resonates and you want to see what's actually available, a range of curated ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time. The right container matters as much as the medicine itself.